Literature DB >> 6125283

Physiological regulation of beta-receptors in man.

A J Wood, R Feldman, J Nadeau.   

Abstract

Previous studies have shown that pharmacological doses of agonists can down-regulate beta receptors. We have shown that alteration of catecholamines within the physiological range is associated with modulation of beta receptor density. The stimulus used to alter catecholamine concentrations in vivo was change in sodium intake. In addition, administration of the beta blocker, propranolol, raised beta receptor density and the rise in receptor density was proportional to the pretreatment catecholamine concentrations. It appears that beta receptors in vivo are in a chronic state of down regulation and that this degree of down regulation parallels the catecholamine concentrations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125283     DOI: 10.3109/10641968209061614

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  7 in total

1.  Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.

Authors:  M C Michel; A Pingsmann; J J Beckeringh; H R Zerkowski; N Doetsch; O E Brodde
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

2.  Association of in vivo β-adrenergic receptor sensitivity with inflammatory markers in healthy subjects.

Authors:  Frank Euteneuer; Paul J Mills; Winfried Rief; Michael G Ziegler; Joel E Dimsdale
Journal:  Psychosom Med       Date:  2012-02-24       Impact factor: 4.312

3.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.

Authors:  Daniel Kurnik; Andrew J Cunningham; Gbenga G Sofowora; Utkarsh Kohli; Chun Li; Eitan A Friedman; Mordechai Muszkat; Usha B Menon; Alastair Jj Wood; C Michael Stein
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

5.  Effect of calcium and beta-adrenoceptor antagonists on beta-adrenoceptor density and Gs alpha expression in human atria.

Authors:  C R Jones; P Fandeleur; B Harris; F R Bühler
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

6.  Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".

Authors:  O E Brodde; A Daul; N Stuka; N O'Hara; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

7.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.